FemTec Health has acquired two companies — a women's reproductive platform and a nutrition platform. Image via avawomen.com

Last month, a Houston-based, tech-enabled health and beauty sciences company made two acquisitions of startups in the femtech space.

FemTec Health, creator of the Awesome Woman comprehensive health care subscription platform, has acquired Ava AG — a women's reproductive digital diagnostics and therapeutics company — and Nutrimedy — a clinical nutrition platform.

Ava, founded by Lea von Bidder in Zurich in 2014, uses artificial intelligence and clinical trials-backed science to help women conceive faster. Per a news release, the FDA-cleared technology has helped over 70,000 women get pregnant.

"What Lea and the Ava team have built is truly innovative. We are excited to add the leader in reproductive health to our portfolio and onto our team," says Dr. Kimon Angelides, FemTec Health founder and CEO, in the July 19 release. "From fertility to contraception, pregnancy support, menopause management, and personalized health insights, Ava's technology is a great addition to make it even easier for women within the FemTec Health platform to take control of their health, all while keeping their data and personal health information one hundred percent private and secure."

FemTec Health's Awesome Woman platform will integrate Ava's technology, adding reproductive health to its list of female-focused health care services which includes vaginal health, hormone balance, sexual wellness, and beauty.

"Ava's vision has always been to be a companion to women along every stage of their lives. With Ava's female health AI integrated into FemTec's care platform, women will finally have access to a fully continuous health journey," says von Bidder in the release. "We are excited to join FemTec in building continuous support for women from puberty to menopause."

Last week, FemTec announced the acquisition of Nutrimedy, a HIPAA-compliant digital health platform founded by Karolina Starczak in Boston in 2016. With the acquisition, Awesome Women members will have access to Nutrimedy's guided nutritional support.

"For many health conditions, nutrition is a key but often neglected component," says Angelides, in the July 25 news release. "Adding Nutrimedy's robust, evidence-based clinical nutrition platform to the Awesome Woman program will be a gamechanger for our subscribers. Whether it's to optimize pregnancy planning, manage menopause symptoms, or for general wellness and prevention, research shows women are seeking personalized, science-backed nutritional support that's easy to use and that they can trust."

With its AI-powered platform, users can access real-time food recommendations and photo food logging. Nutrimedy empowers those suffering from chronic conditions and disruptive food allergies and sensitivities, to make informed dietary decisions in the moment.

"Nutrimedy was started with the mission to improve access to nutrition in healthcare and make it significantly more personalized and actionable in our hectic daily routines," says Starczak in the release. "Within the field of nutrition, conflicting and confusing misinformation is pervasive and prevents most people from making the best decision for their individual health."

Last fall, FemTec Health emerged from stealth with $35 million in fresh VC investment. The company has also acquired Birchbox, Mira Beauty, and Liquid Grids over the past year.

Angelides, a Houstonian, previously told InnovationMap that he was driven to found FemTech Health because there was no holistic platform focused on every phase of women's health.

"Women don't really have a program that's designed for them," Angelides says on the Houston Innovators Podcast. "We embarked in terms of building a platform and a company that would be a single destination for women — one that's not age specific but built around journeys."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.